Cheng-Wei Tang Selected Research

Celecoxib (Celebrex)

7/2020	Celecoxib attenuates hepatocyte apoptosis by inhibiting endoplasmic reticulum stress in thioacetamide-induced cirrhotic rats.
1/2019	Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2.
1/2018	Cyclooxygenase-2 up-regulates hepatic somatostatin receptor 2 expression.
7/2017	Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.
10/2016	Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.
1/2016	Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats.
11/2014	Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes.
7/2013	[Effect of cyclooxygenase-2 inhibitor on CD4+ CD25+ regulatory T cells in mouse hepatocellular carcinoma].
3/2013	Octreotide and celecoxib synergistically encapsulate VX2 hepatic allografts following transcatheter arterial embolisation.
1/2013	Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cheng-Wei Tang Research Topics

Disease

15	Neoplasms (Cancer) 11/2020 - 09/2003
10	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 01/2005
8	Liver Cirrhosis (Hepatic Cirrhosis) 07/2020 - 07/2007
5	Stomach Neoplasms (Stomach Cancer) 03/2022 - 09/2003
5	Obesity 01/2018 - 10/2011
4	Fibrosis (Cirrhosis) 07/2020 - 01/2013
4	Necrosis 11/2017 - 07/2009
4	Body Weight (Weight, Body) 07/2017 - 10/2011
3	Portal Hypertension 07/2020 - 01/2013
3	Inflammation (Inflammations) 01/2019 - 08/2012
3	Neoplasm Metastasis (Metastasis) 01/2018 - 03/2013
3	Adenocarcinoma 01/2017 - 09/2003
3	Hypoxia (Hypoxemia) 10/2016 - 01/2005
2	Lung Neoplasms (Lung Cancer) 11/2020 - 01/2020
2	Pancreatitis 11/2017 - 12/2014
2	Carcinoma (Carcinomatosis) 09/2017 - 04/2009
2	Weight Loss (Weight Reduction) 07/2017 - 10/2013
1	Endotoxemia 01/2022
1	Acute Liver Failure (Fulminant Hepatic Failure) 01/2022
1	Acute-On-Chronic Liver Failure 03/2020
1	Thyrotoxicosis 03/2020
1	Exocrine Pancreatic Insufficiency 11/2017
1	Gastrointestinal Hemorrhage (Hematochezia) 11/2017
1	Peptic Ulcer (Peptic Ulcers) 11/2017
1	Peritonitis 09/2017
1	Tuberculous Peritonitis 09/2017
1	Thrombosis (Thrombus) 08/2017
1	Hydrothorax 08/2017
1	Hepatoblastoma 07/2017
1	Fatty Liver 07/2017
1	Fistula 10/2016
1	Non-alcoholic Fatty Liver Disease 01/2016
1	Ischemia 11/2014
1	Carcinoid Tumor (Carcinoid) 01/2014

Drug/Important Bio-Agent (IBA)

13	Celecoxib (Celebrex)FDA Link 07/2020 - 12/2004
12	Octreotide (Sandostatin)FDA LinkGeneric 01/2018 - 09/2003
10	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2018 - 09/2003
9	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2019 - 12/2004
7	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2005
6	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 07/2020 - 04/2004
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017 - 04/2004
4	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 03/2022 - 01/2013
4	Glucose (Dextrose)FDA LinkGeneric 07/2017 - 10/2011
4	Messenger RNA (mRNA)IBA 04/2017 - 07/2007
3	Thioacetamide (Thioacetamid)IBA 01/2022 - 10/2016
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 11/2014
3	Triglycerides (Triacylglycerol)IBA 07/2017 - 10/2013
3	CholesterolIBA 07/2017 - 10/2013
3	Insulin (Novolin)FDA Link 07/2017 - 10/2013
2	Phosphotransferases (Kinase)IBA 03/2022 - 11/2015
2	AZD 6244IBA 03/2022 - 11/2015
2	somatostatin receptor 2IBA 01/2018 - 09/2003
2	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2018 - 07/2007
2	lanreotide (Somatuline)FDA Link 07/2017 - 01/2014
2	Nonesterified Fatty Acids (NEFA)IBA 07/2017 - 01/2016
2	Dinoprostone (PGE2)FDA Link 10/2016 - 01/2013
2	HDL CholesterolIBA 01/2016 - 10/2013
2	oxidized low density lipoproteinIBA 01/2016 - 10/2007
2	pasireotideIBA 01/2014 - 10/2009
2	Capsules (Microcapsules)IBA 06/2013 - 03/2013
1	trioctyl phosphine oxide (TOPO)IBA 11/2020
1	Adenosine Triphosphate (ATP)IBA 11/2020
1	Long Noncoding RNAIBA 11/2020
1	Tyrosine Kinase InhibitorsIBA 11/2020
1	Gefitinib (Iressa)FDA Link 11/2020
1	Hydroxyproline (4 Hydroxyproline)IBA 07/2020
1	Contrast MediaIBA 03/2020
1	alpha Subunit Hypoxia-Inducible Factor 1IBA 01/2018
1	Proton Pump InhibitorsIBA 11/2017
1	ProcalcitoninIBA 11/2017
1	C-Reactive ProteinIBA 11/2017
1	Interleukin-8 (Interleukin 8)IBA 11/2017
1	CarbohydratesIBA 09/2017
1	AntigensIBA 09/2017
1	tributyl phosphate (TBP)IBA 09/2017
1	Carcinoembryonic AntigenIBA 09/2017
1	Tumor Biomarkers (Tumor Markers)IBA 09/2017
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 07/2017
1	Alanine Transaminase (SGPT)IBA 07/2017
1	PalmitatesIBA 07/2017
1	oil red OIBA 07/2017
1	Liver GlycogenIBA 07/2017
1	Carbon Tetrachloride (Tetrachloromethane)IBA 04/2017
1	RNA (Ribonucleic Acid)IBA 04/2017
1	Biological ProductsIBA 01/2017
1	Endothelial Growth FactorsIBA 10/2016
1	Angiogenesis InhibitorsIBA 10/2016
1	LipidsIBA 01/2016
1	LDL CholesterolIBA 01/2016
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2015
1	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2014
1	Radioisotopes (Radionuclides)IBA 01/2014
1	Apolipoprotein B-48IBA 10/2013

Therapy/Procedure

5	Therapeutics 01/2020 - 07/2011
2	Intraperitoneal Injections 07/2020 - 04/2017
2	Surgical Portasystemic Shunt (Portosystemic Shunt) 08/2017 - 09/2013
1	Transplantation 01/2022
1	Enzyme Replacement Therapy 11/2017
1	Immunomodulation 12/2014
1	Anesthesia 01/2014